Replies to post #405 on Equity Field Notes from temporal sources

[DanWebzster]

GRTS is an Oncology vaccine innovator focusing on difficult-to-treat cancers.

GRTS came to market at a very early stage. The crux of their innovation is to personalize oncology vaccines using each patient's neo-antigen profile.

The market was disappointed at PH1 results ( n=5 )that did not show immediate tumor shrinkage. It does not seem like GRTS was effective at setting expectations for the study.

Subsequently, two of the patients have shown progress. The two cancers that showed a response were:

1) Microsattelite Colorectal Cancer (MCC)
2) Metastacized Lung Cancer in the Liver.

GRTS has decided to conduct a PhII study in MCC

Stock price has not yet responded to the delayed therapeutic interpretation.

MC is ~120M. If the MCC results are repeatable, this stock will be re-rated.

Track for tax loss opty.